Yüklüyor......
Bispecific T-cell engaging antibodies in B-cell precursor acute lymphoblastic leukemias: focus on blinatumomab
Bispecific T-cell engaging antibodies are constructs engineered to bind to two different antigens, one to a tumor-specific target and the other to CD3-positive T cells or natural killer (NK) cells. Blinatumomab engages CD19 and CD3, performing effective serial lysis. The clinical development program...
Kaydedildi:
| Yayımlandı: | Ther Adv Hematol |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
SAGE Publications
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7236391/ https://ncbi.nlm.nih.gov/pubmed/32523659 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620720919632 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|